Rosemont have recently appointed Eric Vick and Tim Busby to join their leadership team.
Eric joins Rosemont as Chief Commercial Officer; bringing a wealth of experience from his 30 years of working in the life sciences industry where he has driven sustainable growth within numerous companies most recently at Ethypharm. Eric has a strong track record of building new business channels and stated, “I’m very excited to join Rosemont, they have a long history of success tied with ambitious plans for portfolio development, geographic expansion, and delivery of important solutions for customers and patients.”
Tim joined Rosemont in mid-2020 as Chief Financial Officer following the company’s change of ownership. Since joining the business Tim has successfully driven step changes in business growth and performance, managed M&A processes, and implemented finance and systems transformations. Tim brings with him over 20 years of experience operating in various Chief Financial Officer and Finance Director roles. Teamed with Tim’s extensive private equity experience across a variety of sectors; Rosemont have already benefitted from his appointment and direction as an active member of their Board of Directors.
Chief Executive Officer, Howard Taylor commented “Following our recently celebrated independence; it’s essential for Rosemont to have strong leaders in place so that we can continue to grow and thrive as a market leader. Both Eric and Tim’s experience, drive and orchestration are crucial elements to the success of our company’s growth and expansion, with a particular focus on international development and finding partners to broaden our portfolio of novel-delivery medicines for patients that need them.”
Announcement featured in the Appointment section of PharmaTimes Media Ltd’s March magazine issue.